The company blamed its Q2 content slate and price increases for the subscriber miss.Technologyread more
Corporate earnings forecasts for the second quarter were lowered so much that companies are easily beating them.Market Insiderread more
The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
IBM's year-over-year revenue has now declined for four quarters in a row. Impact from Red Hat is not yet factored into the company's guidance.Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt. And growth is entirely dependent on Netflix's...Technologyread more
Prosecutors in Masschusetts have dropped a criminal case against actor Kevin Spacey, who had been accused of groping an 18-year-old man.Entertainmentread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
Trade negotiations between the world's two largest economies are stuck at a standstill, the Wall Street Journal reported Wednesday.Marketsread more
House Speaker Nancy Pelosi says she wants her chamber to vote on a debt ceiling and budget deal by July 26.Politicsread more
Philips has acquired a start-up that texts you about your poop. That's Medumo, a Boston-based company, which works with hospitals to guide their patients through common...Technologyread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
Responding to a call from prominent oncologists to slow the rise in cancer drug prices, Eli Lilly Chairman and CEO John Lechleiter said Thursday that all aspects of care need to be addressed, including the high costs of Obamacare for many Americans.
"We're ... very concerned that patients who need these medicines be able to gain access to these medicines and afford this medicines," he told CNBC's "Squawk Box, " but added: "Medicines are a small fraction of what the total cost of cancer care comprises."
The journal Mayo Clinic Proceedings, where more than 100 cancer doctors made their drug cost plea on Thursday, cited research that showed an escalation in cancer medicine prices by an average of $8,500 a year over the past 15 years.
"In cancer in particular, we're making great strides with some of the new medicines that have been introduced lately," said Lechleiter. "[But] there's a lot of risk to bring these medicines through the pipeline," because many of them fail to work.
Looking at drug costs overall, the Lilly chief said, "We need an insurance system that provides adequate coverage for all the elements of care, including medicines that patients need."
"Some of the insurance policies we've seen offered through these [Obamacare] exchanges, the premiums are low but the co-pay or co-insurance or the deductible associated with gaining access to medicine is too high for many people," he said.
Lechleiter appeared on CNBC following the release of Lilly's earnings report. It said adjusted earnings were 90 cents a share, which by 16 cents.
Revenue also came in above forecasts, despite being "hit by 8 percentage points, a downdraft, from the strengthening dollar," he said.
Lilly raised its full-year forecast, even with the expiration of some key patents, citing new drug approvals and significant pipeline progress.